Tectonic Therapeutic
Watertown, US · Founded 2019 · 69 employees on LinkedIn · 12 known investors
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.
Founders & leadership
Tectonic Therapeutic was founded in 2019 by Timothy A. Springer, Andrew C. Kruse, Timothy Springer, and Andrew Kruse.
TA
Timothy A. SpringerCo-Founder
AC
Andrew C. Kruse
TS
Timothy SpringerCo-founder
AK
Andrew KruseCo-founder
AR
Alise ReicinExecutive
DL
Daniel LochnerExecutive
MS
Marc SchwabishExecutive
PM
Peter McNamaraExecutive
MK
Marcella K. RuddyExecutive
CC
Christian CortisExecutive
GM
Geoffrey MacKayExecutive
CM
Christopher MasonExecutive
Investors · 12
EcoR1 CapitalSan Francisco
Vida VenturesLos Angeles
Ally Bridge GroupreportedNew York
ClarusreportedCambridge
Polaris PartnersreportedBoston · $500K – $5Mvia Terry McGuire · board
Soleus CapitalreportedGreenwich
Also in the syndicate · 6
Adage Capital Partners LPDeep Track CapitalFarallon Capital Management, L.L.C.StemPoint Capital LPTAS PartnersWoodline Partners LP
Reported raises · per SEC filings
Form D private placements$333.1M disclosed across 4 rounds · 2016–2025
▶$185MraisedFeb 2025 · 29 investors · BiotechnologyRule 506(b)
▶$185MraisedFeb 2025 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alise ReicinExecutive Officer, Director
- Phillip B. DonenbergDirector
- Timothy SpringerDirector
- Daniel LochnerExecutive Officer
- Terrance McGuireDirector
- Marc SchwabishExecutive Officer
- Peter McNamaraExecutive Officer
- Marcella K. RuddyExecutive Officer
- Praveen P. TipirneniDirector
- Stefan VitorovicDirector
- Offering amount
- $185M
- Amount sold
- $185M
- Sales commissions
- $11.1M
- Placement agents
- Piper Sandler & Co., Leerink Partners LLC, TD Securities (USA) LLC, Wells Fargo Securities, LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80.1MraisedApr 2021 · 23 investors · BiotechnologyRule 506(b)
▶$80.1MraisedApr 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew KruseDirector
- Timothy A. SpringerDirector
- Terry McGuireDirector
- Christian CortisExecutive Officer
- Stefan VitorovicDirector
- Praveen TipirneniDirector
- Alise ReicinExecutive Officer, Director
- Offering amount
- $80.1M
- Amount sold
- $80.1M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$60.5MraisedFeb 2018 · 15 investors · BiotechnologyRule 506(b)
▶$60.5MraisedFeb 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey MacKayExecutive Officer, Director
- Christopher MasonExecutive Officer
- Scott RequadtDirector
- Kim WarrenExecutive Officer
- Deanna PetersenExecutive Officer
- Joshua ResnickDirector
- Christopher PaigeDirector
- Katina DortonExecutive Officer
- Ian ClarkDirector
- Bruce BoothDirector
- Offering amount
- $61M
- Amount sold
- $60.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$7.5MraisedAug 2016 · 3 investors · BiotechnologyRule 506(b)
▶$7.5MraisedAug 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey MacKayExecutive Officer, Director
- Christopher MasonExecutive Officer
- Kim WarrenExecutive Officer
- Joshua ResnickDirector
- Deanna PetersenExecutive Officer
- Bruce BoothDirector
- Scott RequadtDirector
- Christopher PaigeDirector
- Offering amount
- $25M
- Amount sold
- $7.5M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapContext Therapeutics31 shared keywordsContext Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
Dialectic Therapeutics31 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Kite Pharma28 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with Tectonic Therapeutic for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Tectonic Therapeutic do?
- Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™. The company focuses on therapeutic areas with significant unmet medical needs where current treatment options are limited or absent.
- Who founded Tectonic Therapeutic?
- Tectonic Therapeutic was founded by Timothy A. Springer, Andrew C. Kruse, Timothy Springer, Andrew Kruse in 2019.
- Who are Tectonic Therapeutic's investors?
- Tectonic Therapeutic's investors include EcoR1 Capital, Vida Ventures, Ally Bridge Group, Clarus, Polaris Partners, Soleus Capital.
- How much funding has Tectonic Therapeutic raised?
- Tectonic Therapeutic has disclosed $333.1M raised across 4 rounds.
- Where is Tectonic Therapeutic headquartered?
- Tectonic Therapeutic is headquartered in Watertown, US.